As potency increases across the industry, the need for high performance containment through the final stages of production has been in increasingly high demand. Due to the concentration and toxicity of the APIs and HPAPIs used in the formulation of OSD pills, the risk of exposure during the often messy packaging process is more critical than ever before. Proper engineering controls and risk mitigation should be in place to safely manufacture and package the medicines that the world relies on.